Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04821063
Recruitment Status : Completed
First Posted : March 29, 2021
Last Update Posted : August 26, 2021
Sponsor:
Information provided by (Responsible Party):
Italfarmaco

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 18, 2021
Actual Study Completion Date : June 18, 2021